Overview

Characterizing IgG4-RD With 68Ga-FAPI PET/CT

Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
68Ga-FAPI has been developed as a tumor-targeting agent as fibroblast activation protein is overexpressed in cancer-associated fibroblasts and some inflammation,such as IgG4-related disease.And it might be more sensitive than FDG in detecting a certain type of inflammations according to our preliminary research.Thus this prospective study is going to investigate whether 68Ga-FAPI PET/CT may be superior for diagnosis, therapy response assessment and follow-up of IgG4-related disease.
Phase:
Early Phase 1
Details
Lead Sponsor:
Peking Union Medical College Hospital
Treatments:
Immunoglobulin G